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OBJECTIVE: Bardet-Biedl syndrome is a genetic, multisystem disorder that causes severe visual impairment. This
condition is characterized by retinal dystrophy, obesity, digit anomalies, renal disease, and hypogonadism. The
purpose of this study was to analyze visual acuity and full-field electroretinogram findings in patients with the
Bardet-Biedl syndrome phenotype.
METHODS: The visual acuity of a group of 23 patients (15 males) with ages ranging from 6-36 years
(mean=15.8¡6.4; median=14.7) was assessed. Retinal function was evaluated by full-field electroretinography,
and dark-adapted thresholds were assessed.
RESULTS: Visual acuity in the better-seeing eye was 20/40 or better in 5 patients (21.7%), 20/50-20/150 in 13 (56.5%)
patients, 20/200-20/400 in 2 (8.7%) patients and worse than 20/400 in one (4.3%) patient. The mean acuity in the
better-seeing eye was 0.7¡0.6 logMAR (20/100, Snellen equivalent). Scotopic rod and maximal responses were non-
detectable in 21 (91.3%) patients, and cone responses were non-detectable in 15 (65.2%) patients. Elevated dark-
adapted visual thresholds were observed in all 19 patients who were able to be assessed, with 10 (52.6%) patients
having thresholds greater than 30 dB.
CONCLUSIONS: In a relatively young cohort of patients with Bardet-Biedl syndrome, only 21% had 20/40 or better
vision. ERG scotopic responses were absent in the majority of cases, with cone responses being observed in less than
half of cases. These findings showed the early deleterious effects in retinal function and visual acuity caused by this
condition.
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INTRODUCTION
Bardet-Biedl Syndrome (BBS), first described by Bardet in
1920 and Biedl in 1922, is a rare autosomal recessive disorder
that affects numerous tissues and causes severe visual
impairment (1). The estimated prevalence of BBS ranges
from 1:125,000 in Europe to 1:18,500 in certain isolated
populations in Canada (2,3). The clinical diagnosis of BBS is
based on the presence of at least four of five cardinal features:
retinal dystrophy, dystrophic extremities (polydactyly, syn-
dactyly, brachydactyly), obesity, hypogenitalism in men
only, and renal disease (4,5). BBS is currently considered a
‘ciliopathy,’ with the underlying defects affecting the basal
bodies of ciliated cells, such as the connecting cilium in the
outer retina (6). BBS patients variably display all common
ciliopathy features: polydactyly, cystic kidneys, retinal
degenerations, and situs inversus. To date, mutations in any
one of 16 different genes can cause this phenotype (7-11).
Ocular manifestations of BBS include a marked reduction
of electroretinogram (ERG) amplitude and notable degree of
retinal pigmentary degenerative changes in early childhood
(1). Retinal function in BBS patients has been studied by full-
field ERG and shows a variable expression of rod-cone or
cone-rod dysfunction (1,5,12-16). In BBS carriers, abnormal
rod-mediated responses have been detected by full-field
ERG, and areas of local dysfunction in the central retina
have been observed by multifocal ERG (17,18).
The natural course of BBS is characterized by poor visual
prognosis, with central vision declining by 1 line per year on
the logMAR chart and peripheral vision deteriorating 0.19
log units per year in dark-adapted thresholds (12). The optic
disks and retinal vessels are normal in infancy; disk pallor
and attenuated retinal vessels develop with age. Pigmentary
changes are observed in the peripheral fundus (19,20). Night
blindness usually manifests by eight years of age and
progresses to complete blindness by 16-20 years of age (7).
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Although different forms of BBS can correlate with
specific mutations, demonstrating the genetic heterogeneity
in this condition, several studies have suggested that
molecular investigations do not show clear phenotype-
genotype correlations. Therefore, the diagnosis is still made
using clinical data (10,21). Moreover, BBS may be character-
ized by profound inter- and intrafamilial clinical variability,
which may be partially explained by the presence of second-
site modifiers (9). Because BBS has a variable clinical
presentation, the purpose of this retrospective study was
to analyze visual acuity (VA) and full-field ERG findings in
patients with the BBS phenotype recruited from a public
university hospital in Brazil.
MATERIALS AND METHODS
Participants. Participants were patients with the Bardet-
Biedl syndrome phenotype who were referred to the
Electrophysiology of Vision Laboratory at the Department
of Ophthalmology of the Federal University of Sa˜o Paulo,
Sa˜o Paulo, Brazil for assessment from October 1998 to
August 2010. During this time frame, 3,282 patients were
referred to our laboratory, and the Bardet-Biedl syndrome
group comprised 0.8% of these patients. A history of
consanguinity was obtained by a personal interview. Non-
ocular abnormalities were determined by history and/or
available medical records; these cardinal features were not
specifically assessed in these patients. This study was
approved by the Federal University of Sa˜o Paulo’s
Committee of Ethics in Research and followed the tenets
of the Declaration of Helsinki. Written informed consent
was obtained from each patient or his/her parents or
guardians after researchers explained the purpose,
procedures, and possible risks and benefits of the study.
Retinal dystrophy type was classified according to the
standard clinical criteria, considering history, fundus exami-
nation and previous full-field ERG responses (recorded
from both eyes with bipolar contact lens electrodes) as rod-
cone or cone-rod dystrophy. Inclusion criteria were the
presence of at least four of the following cardinal features:
retinal dystrophy, obesity, extremity abnormalities, hypo-
genitalism in males, and renal abnormalities.
Procedures
Ophthalmic Examination. An ophthalmic examination of
both eyes was performed by a retina specialist (SSW),
including slit-lamp, refraction, and dilated indirect
ophthalmoscopy. Best-corrected visual acuity (BCVA) was
measured in each eye using a retro-illuminated Early
Treatment Diabetic Retinopathy Study Chart built with
Tumble ‘‘E’’ optotypes presented at a distance of 4 m.
Ocular motility was assessed using cover/uncover and
alternate cover testing for distance and near vision testing,
with and without glasses, with emphasis on the diagnosis of
strabismus and nystagmus.
Full-Field Electroretinography. A minimum pupil
diameter of 6 mm was obtained after administering a drop
of tropicamide 1% with a drop of phenylephrine 10%, and
all subjects were dark-adapted for 30 min. Under dim red
illumination, a bipolar contact lens electrode (Burian-Allen
bipolar electrode, Hansen Ophthalmic Development Lab,
Coralville, IA, USA) was placed on the corneal surface. The
corneal surface was anesthetized with two drops of
tetracaine 1.0%, and a drop of methylcellulose 2% was
placed on the inside surface of the contact lens for protection
and to ensure good electrical contact. A gold cup ground
electrode was applied to the earlobe. All stimuli were
presented in a Ganzfeld dome (LKC Technologies Inc.,
Gaithersburg, MD, USA). Signals were amplified (gain,
910,000; 0.3–500 Hz), digitized, averaged, saved, and
displayed by a digital plotter (UTAS E-3000 System, LKC
Technologies Inc., Gaithersburg, MD, USA). ERGs were
recorded using the standard International Society for
Clinical Electrophysiology of Vision (ISCEV) protocol (22).
Stimulus and recording details have been described
previously (23). The peak-to-peak amplitude (mV) and the
implicit time (ms) from each step of the ISCEV standard
protocol were determined. The oscillatory potential amp-
litude was calculated as the sum of each wavelet and
automatically analyzed by the UTAS E-3000 system.
Dark-adapted thresholds. Dark-adapted thresholds
were obtained using the Scotopic Sensitivity Tester (SST-1)
(LKC Technologies Inc., Gaithersburg, MD, USA). The SST-1
uses a full-field green LED (lmax = 572 nm) as its stimulus in
dark adaptometry mode, with a maximum intensity of -2.15
log cd/m2 at 30 dB. The SST-1 stimulus intensity decreases
in 1-dB increments and increases in 5-dB increments, which
range from 0 to 30 dB. The SST-1 thresholds were obtained
using a two-alternative forced-choice staircase protocol
(stimulus vs. non-stimulus, n = 3, decreasing in 1-dB
increments). The dark-adapted final threshold was
obtained by repeating this protocol three times and
averaging the results (24).
Statistical Analysis
Data from ERG parameters (peak-to-peak amplitude and
implicit time) from each step according to the ISCEV
standard protocol were measured and compared with
normative data from our own laboratory. A normality test
was used to confirm the data distribution. A Spearman’s
rank correlation coefficient was performed to investigate
possible associations between a) BCVA in the better-seeing
eye and age, b) BCVA and peak-to-peak amplitude for cone
responses, and c) BCVA and peak-to-peak amplitude for 30-
Hz flicker responses. A result was considered statistically
significant if the p-value was less than 0.05.
RESULTS
We examined 23 patients (15 males) from 22 families with
ages ranging from 6-36 years (mean= 15.8¡6.4; med-
ian = 14.7). A summary of the major clinical characteristics
is presented in Table 1. A history of consanguinity was
found in 11 participants (47.8%). The patients’ self-reported
race was white in 14 (61%) patients, mixed white/black in
eight patients (35%), and black in one patient (4%). The most
frequent presenting visual symptoms were as follows: night
vision loss in 22 patients (95.6%), visual acuity loss in 19
patients (82.6%), and visual field loss in 13 patients (56.5%).
A 12-year-old male patient had no visual symptoms (case
#8).
High ametropias were found in six patients (26.0%), with
four patients reporting high myopia (SE#-6.0 D) and two
reporting high hyperopia (SE$6.0 D). Severe retinal
dystrophy was found in all patients. A rod-cone pattern
was observed in 20 patients (86.9%), with the remaining
three patients showing cone-rod dystrophy. Ophthal-
moscopic changes were classified according to fundus
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photographs (when available) or fundus descriptions. Data
were available from 21 of the 23 examined patients. The
most frequent fundus changes were attenuated vessels in 14
patients (67.0%), widespread retinal epithelium abnormal-
ities in 14 patients (67.0%), disk pallor in nine patients
(42.8%), macular abnormalities in nine patients (42.8%), and
peripheral pigmentation in five patients (23.8%).
Six patients (26.0%) presented manifest bilateral nystag-
mus. On the cover test, three subjects presented esotropia,
two presented exotropia, and one presented intermittent
exotropia; the remaining 17 subjects had orthoposition of
the visual axes. Both nystagmus and strabismus were found
in three patients (13.0%).
Visual Acuity
The BCVA distribution from 21 BBS patients is shown in
Table 1. BCVA in the better-seeing eye was 20/40 or better in
five patients (21.7%), 20/50-20/150 in 13 patients (56.5%),
20/200-20/400 in two patients (8.7%), andworse than 20/400 in
one patient (4.3%). Two patients were uncooperative in the
visual acuity measurement. The mean VA was 0.7¡0.6
logMAR (20/100, Snellen equivalent) in the better-seeing eye
and 0.9¡0.6 logMAR (20/160, Snellen equivalent) in the worse-
seeing eye. No significant correlation was found between age
and BCVA (logMAR) in the better-seeing eye (p=0.24).
Full-field ERG
ERG abnormalities were found in all 23 patients.
Representative standard full-field ERG recordings from one
eye from a healthy normal subject, one patient with rod-cone
dystrophy (case#2), and one patient with cone-rod dystrophy
(case#3) are shown in Figure 1. Figure 2 summarizes the ERG
parameters for scotopic and photopic retinal function from
BBS patients compared with our own normative data
(mean¡2 SD), as represented by rectangles, similar to the
previously shown graphic model (13,25). Rod scotopic
responses were non-detectable in 20 patients, with only three
patients reporting remaining rod function below the lower
normal limit. Four patients had detectable mixed scotopic
responses, with two patients responding (cases #8 and #3)
within the normal limits and two patients (cases#9 and #16)
responding below the lower normal limits; the remaining
patients had non-detectable responses. Cone function assessed
by single-flash cone responses was present in nine patients; all
patients except case #2 had responses below the normal
limits. Cone responses for 30-Hz flicker were detected in 16
patients and non-detectable in seven patients; all detected
responses were below the normal limits. No correlation was
found between BCVA and peak-to-peak amplitude for cone
responses (p=0.08) or between BCVA and peak-to-peak
amplitude for 30-Hz flicker responses (p=0.76).
Dark-adapted thresholds
Elevated dark-adapted visual thresholds were found in
all 19 patients who were able to be assessed, with 10 patients
(52.6%) having thresholds higher than 30 dB. The mean
threshold was 22.7¡9.04 dB with a median of 30 dB.
Non-ocular findings
Of the 23 patients, 21 patients (91.3%) were obese, 18
patients (78.3%) presented digital anomalies, 18 patients
(78.3%) had mental retardation, and 7 patients (30.4%) had
renal anomalies.
DISCUSSION
The present study showed no correlation between BCVA
in the better-seeing eye and age, thereby corroborating


















1 6 M mixed N VA, NV loss Uncooperative NA Uncooperative rod-cone Y Ortho
2 8 M white N VA, NV loss 20/100 +7.00 MA rod-cone N Ortho
3 9 M mixed N VA, NV loss 20/40 +11.75 AV, DP, WRPEA cone-rod N Ortho
4 10 M white Y VA, NV loss 20/160 -11.50 WRPEA rod-cone Y XT
5 11 M white N VA, NV loss 20/40 +4.25 WRPEA rod-cone N Ortho
6 11 M white Y NV, VF loss 20/125 +2.25 AV, DP, WRPEA rod-cone N Ortho
7 12 F mixed N VA, NV, VF loss 20/125 +0.50 WRPEA rod-cone N X(T)
8 12 M white N None 20/40 NA AV, DP, MA cone-rod N Ortho
9* 12 M white Y VA, NV, VF loss 20/40 -2.50 AV, WRPEA rod-cone N ET
10 13 F white N NV, VF loss 20/125 -0.50 MA, PP rod-cone Y XT
11 14 M mixed Y VA, NV, VF loss 20/160 +4.50 AV, MA, PP, WRPEA cone-rod Y Ortho
12 14 M white Y VA, NV, VF loss 20/100 +2.00 MA, WRPEA rod-cone N Ortho
13* 14 M white Y VA, NV, VF loss 20/50 -2.00 AV, MA rod-cone N ET
14 15 F white N VA, NV, VF loss 20/80 -8.50 AV, MA rod-cone N Ortho
15 15 F mixed N VA, NV loss 20/125 NA WRPEA rod-cone N Ortho
16 16 F white Y VA, NV loss 20/80 -9.25 AV, DP, WRPEA rod-cone N Ortho
17 17 M black Y VA, NV, VF loss 20/63 +1.50 AV, DP, WRPEA rod-cone N Ortho
18 17 F white Y VA, NV, VF loss 20/125 -4.75 AV, DP, MA, WRPEA rod-cone N Ortho
19 18 M white N VA, NV, VF loss 20/50 NA AV, DP, MA, PP, WRPEA rod-cone N Ortho
20 19 M mixed Y NV, VF loss 20/25 +2.25 AV, DP, PP rod-cone N Ortho
21 20 F white Y VA, NV loss 20/200 NA AV, WRPEA rod-cone N Ortho
22 28 M mixed N VA, NV loss Uncooperative NA AV, DP, PP rod-cone Y ET
23 36 F mixed N VA, NV, VF loss LP -6.50 NA rod-cone Y Ortho
*brothers from a consanguineous marriage; mixed — black/white; BCVA – best-corrected visual acuity; SE – spherical equivalent; VA – visual acuity; NV –
night vision; VF – visual field; NA – not available; MA – macular abnormalities; AV – attenuated vessels; DP – disk pallor; WRPEA – widespread retinal
pigmented epithelium abnormalities; PP – peripheral pigmentation; ET – esotropia; XT – exotropia; and X(T) – intermittent exotropia.
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previous reports in cohorts of three genetic BBS variants
(1,16). However, other reports have shown decreased vision
in the first decades of life, as found in our studied sample
(5,21). Good BCVA in the better-seeing eye ($20/40) was
found in only five patients (21.7%) in our study. These
results are similar to those results reported in a group of 10
BBS patients, with four patients showing good visual acuity
(16). Legal blindness (BCVA in the better-seeing eye #20/
200) was present in two (8.7%) older patients (cases#21 and
23). Longitudinal data from these patients should be
pursued to detect the visual acuity loss rate (in lines/year),
as previously demonstrated (12). The frequency of nystag-
mus or strabismus was 26%. In six patients with strabismus,
there was a fair distribution between esotropias and
exotropias. Similar findings have been described in young
BBS patients presenting nystagmus, but a tendency to
exotropia was not found in our cohort (20,21).
The lack of correlations between BCVA in the better-
seeing eye and peak-to-peak amplitude for cone responses
and between BCVA and peak-to-peak amplitude for 30-Hz
flicker responses was not unusual. Because full-field ERG
may not be sensitive enough to detect minimal regional
responses from the central retina, these findings confirm
previous reports (16,19).
The rod-cone degeneration with no rod responses and
elevated dark-adapted thresholds observed in the vast
majority of patients confirm previous reports (13,15).
Measurable cone-flicker responses were detected in 28/36
patients, and these responses can be used to objectively
follow the natural history of the disease (13). In the current
Figure 1 - Representative standard full-field ERG waveforms (rod, mixed, oscillatory potentials, cone, and 30 Hz-flicker responses) with
amplitudes in mV (Y axis) and time in ms (X axis) from a healthy age-matched subject (upper panels), a patient with Bardet-Biedl
syndrome (case #2) presenting rod-cone dystrophy (middle panels), and a patient with Bardet-Biedl syndrome (case #3) presenting
cone-rod dystrophy (lower panels).
Figure 2 - ERG parameters for rod, mixed, cone, and 30-Hz flicker responses recorded from one eye of 23 patients with Bardet-Biedl
syndrome compared with normative data from our own laboratory (rectangle=mean¡2 SD).
Visual acuity and retinal function in Bardet-Biedl syndrome
Berezovsky A et al.
CLINICS 2012;67(2):145-149
148
study, all patients had severely reduced or extinguished
ERG parameters. These findings were also seen in previous
studies in young patients and a series of patients with BBS
mutations, with younger patients showing less photorecep-
tor degeneration (1,12). These data show that BBS retinal
disease, which is primarily a degeneration of photorecep-
tors, must affect functional processes common to both rods
and cones. Both central (acuities) and more peripheral
(thresholds) functions are affected (12). Beside functional
abnormalities measured by ERG, disrupted inner and outer
segment layers and thinned RPE have been described in vivo
by Fourier-domain OCT with inner retinal layer preserva-
tion (6,16).
Male predominance was found in our cohort, with a
male-to-female ratio of 1558 being observed. These results
are consistent with previously reported findings in both
adults and pediatric BBS patients (20,21). However, other
studies have described a slight female predominance (5).
These discrepancies could be explained by the low
incidence of this recessive condition, which leads to studies
with a limited number of participants.
In most developing countries, access to modern molecular
diagnostic techniques is extremely limited, reinforcing the
need for a detailed phenotypic description to achieve
precise clinical diagnoses of several genetic eye disorders,
including BBS. In this highly variable disease, not all
features are present, as described in a recent case report of
two brothers with proven BBS1 mutation without obesity
(26). Efforts to make these molecular diagnostic techniques
available to all patients with genetic ocular diseases should
be pursued.
ERG scotopic responses were absent in the vast majority
of cases, and cone responses remained in less than half of
patients. These results confirm the early deleterious effects
in retinal function and visual acuity caused by BBS.
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